1-(2-benzofuryl)-2-aminopropane | 30455-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 1-(2-benzofuryl)-2-aminopropane
• 英文别名: 1-(benzofuran-2-yl)propan-2-amine；2-[2-methyl-2-aminoethyl]benzofuran；2-(2-Amino-n-propyl)-benzofuran；1-(1-benzofuran-2-yl)propan-2-amine
• CAS: 30455-73-3
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: QGLBWEFCBFEAPH-UHFFFAOYSA-N

物化性质

• 沸点：
  277.1±15.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-benzofuryl)-2-aminopropane 在 盐酸 、 lithium aluminium tetrahydride 作用下， 生成 (2-benzofuran-2-yl-1-methyl-ethyl)-ethyl-amine; hydrochloride
  参考文献：
  名称：

  The potential rewarding and reinforcing effects of the substituted benzofurans 2-EAPB and 5-EAPB in rodents

  摘要：

  Accounts regarding the use of novel psychoactive substances continue to escalate annually. These include reports on substituted benzofurans (SBs), such as 1-(1-benzofuran-2-yl)-N-ethylpropan-2-amine (2-EAPB) and 1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine (5-EAPB). Reports on the deaths and adverse consequences from the use of SBs warrant the investigation of their mechanism, possibly predicting the effects of similar compounds. Accordingly, we investigated the possible rewarding and reinforcing effects of 2-EAPB and 5-EAPB through conditioned place preference (CPP), self-administration, and locomotor sensitization tests. We also determined the possible influence of 2-EAPB and 5-EAPB administration on dopamine- and plasticity-related proteins in the nucleus accumbens and ventral tegmental area. 2-EAPB and 5-EAPB induced CPP at different doses and were self-administered by rats. Only 5-EAPB induced locomotor sensitization in mice. 2-EAPB and 5-EAPB did not alter the expressions of dopamine D1 and D2 receptors in the nucleus accumbens, nor changed tyrosine hydroxylase and dopamine transporter expressions in the ventral tegmental area. Both 2-EAPB and 5-EAPB enhanced deltaFosB, but not transcription factor cyclic AMP-response-element binding protein and brain-derived neurotrophic factor in the nucleus accumbens. Hence, the potential rewarding and reinforcing effects on rodents induced by 2-EAPB and 5-EAPB may possibly be associated with alterations in other neurotransmitter systems (besides mesolimbic) and/or neuro-plastic modifications.

  DOI：

  10.1016/j.ejphar.2020.173527
• 作为产物：
  描述：

  2-(2-nitro-propenyl)-benzofuran 在 lithium aluminium tetrahydride 、 甲醇 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 1-(2-benzofuryl)-2-aminopropane
  参考文献：
  名称：

  SUBSTITUTED HETEROCYCLIC COMPOUNDS

  摘要：

  本发明涉及式I或XI的取代杂环化合物： 或其药用可接受的盐或N-氧化物或季铵盐，其中所述成员在此提供，并且它们的组合物和使用方法，这些方法是组胺H24受体抑制剂，用于治疗组胺H24受体相关的疾病或疾病，包括例如炎症性疾病或疾病，瘙痒和疼痛。

  公开号：

  US20100240671A1

文献信息

• CYANOFLUOROPYRROLIDINE DERIVATIVE
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1627870A1

  公开（公告）日：2006-02-22

  A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R1 and R2 are as defined in the specification, X represents a single bond or a C1-3 alkylene group, and R3 represents a group represented by the formula: -N(R4)COR5, -N(R4)SO2R5, -NR4R6, -SO2R5, -SO2NR4R5, -OCONR4R5, -CH=CH-R7 or -C≡C-R7, or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y3 group)].

  一个用于预防或治疗可以通过抑制二肽基肽酶IV（DPPIV）来改善的疾病或病症的氰基氟代吡咯烷化合物，其具有公式（I）或药用上可接受的盐或水合物： [其中 A代表氢原子或氟原子， R1和R2如说明书中定义， X代表单键或C1-3亚烷基，并且 R3代表由公式表示的基团：-N(R4)COR5，-N(R4)SO2R5，-NR4R6，-SO2R5，-SO2NR4R5，-OCONR4R5，-CH=CH-R7或-C≡C-R7，或代表从至少含有一个氧和/或硫原子，并可能进一步含有氮原子的杂芳基组中选择的一个杂芳基组，以及一个6-成员氮杂芳环或9至11-成员的稠环（其中杂芳基组可以与一个或多个来自代Y3基团的取代基取代）。]
• Cyanofluoropyrrolidine derviative
  申请人：Fukushima Hiroshi

  公开号：US20060293297A1

  公开（公告）日：2006-12-28

  A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R 1 and R 2 are as defined in the specification, X represents a single bond or a C 13 alkylene group, and R 3 represents a group represented by the formula: —N(R 4 )COR 5 , —N(R 4 )SO 2 R 5 , —NR 4 R 6 , —SO 2 R 5 , —SO 2 NR 4 R 5 , —OCONR 4 R 5 , —CH═CH—R 7 or —C≡C—R 7 , or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y 3 group)].

  一种氰基氟吡咯烷化合物，化学式为(I)，或其药学上可接受的盐或水合物，能够作为一种抑制二肽基肽酶IV（DPPIV）并预防或治疗疾病或症状的药物，例如糖尿病，免疫性疾病等。其中A代表氢原子或氟原子，R1和R2如规范中所定义，X代表单键或C13烷基，R3代表由以下公式表示的基团：—N(R4)COR5，—N(R4)SO2R5，—NR4R6，—SO2R5，—SO2NR4R5，—OCONR4R5，—CH═CH—R7或—C≡C—R7，或表示从含有至少一个氧和/或硫原子的杂环芳基中选择的杂环芳基，该杂环芳基还可以包含一个氮原子以及一个6元氮含杂环芳基或9-11元的缩合环（其中杂环芳基可以用来代替一个或多个取代基Y3）。
• 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
  申请人：Barrow C. James

  公开号：US20080015233A1

  公开（公告）日：2008-01-17

  The present invention is directed to 2,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及2,4,6-取代吡啶衍生物化合物，其是beta-分泌酶酶的抑制剂，可用于治疗涉及beta-分泌酶酶的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及beta-分泌酶酶的这种疾病的治疗中的使用。
• SUBSTITUTED HETEROCYLIC COMPOUNDS
  申请人：Incyte Corporation

  公开号：US20130296327A1

  公开（公告）日：2013-11-07

  The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

  本发明涉及式I或式XI的取代杂环化合物：或其药学上可接受的盐或N-氧化物或季铵盐，其中成员构成在此提供，以及它们的组合物和使用方法，它们是组胺H4受体抑制剂，用于治疗组胺H4受体相关的疾病或疾病或疾病，包括例如，炎症性疾病或疾病，瘙痒和疼痛。
• Heteroarylisopropylamines as MAO inhibitors
  作者：Gabriel Vallejos、Angélica Fierro、Marcos Caroli Rezende、Silvia Sepúlveda-Boza、Miguel Reyes-Parada

  DOI：10.1016/j.bmc.2005.04.045

  日期：2005.7

  The in vitro monoamine oxidase inhibitory (MAOI) activities of 11 heteroarylisopropylamines vis-a-vis MAO-A and MAO-B were described and interpreted in terms of possible interactions with the enzyme active site. Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin. (c) 2005 Elsevier Ltd. All rights reserved.